Filter posts

NYT Columnist: Insurance Industry “Looking at the Costs of Sovaldi in the Wrong Way”

Margot Sanger-Katz’s article on a new drug that treats hepatitis C notes that despite the …

Treating Hepatitis C: Too Costly Not to Act

Today, The Hill published an op-ed – Treating hepatitis C: Too costly not to act …

New Report: Innovation in Hepatitis C Treatment

Today, the California Healthcare Institute released a report on the public health impact of Hepatitis …

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original …

Beggar-Thy-Neighbor Medicine: Wall Street Journal Op-Ed

In an editorial about specialty drug prices, the Wall Street Journal writes: “To understand how …

Synthetic Biology: The Sword in the Stone to Defeat Devastating Diseases

On July 17th, 2014 the House held a hearing titled: Subcommittee on Research and Technology …

Jim Greenwood Talks 21st Century Cures with Chairman Fred Upton

Recently, BIO CEO and President Jim Greenwood sat down with House Energy and Commerce Chairman …

The Cancer Death-Panel App

In an article for the New York Post, Robert Goldberg, vice president of the Center …

Grass Stains, Flip Flops, Water Fights… and Biotech!

July is notorious for the beaming rays and hot summer weather. Luckily our atmosphere protects …

AIR 340B New Report: Contract Pharmacy Growth in 340B

Today, the Alliance for Integrity and Reform of 340B (AIR 340B) released a white paper …